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APOBEC3G
APOBEC3Axist in two forms containing either a single cytidine deaminase domain (CDA) or
two CDAs. Strikingly, the proteins that are capable of effectively inhibiting the infectivity of Vif-deﬁcient HIV-
1 (HIV-1ΔVif), such as APOBEC3G (A3G), contain two CDAs. In contrast, single-domain APOBEC3 proteins
such as APOBEC3A (A3A) are weak inhibitors of HIV-1ΔVif, even though A3A is an active cytidine deaminase
and a potent inhibitor of retrotransposon mobility. Here, we demonstrate that the ability to bind to Gag and
package into HIV-1 virions is entirely contained within the amino-terminal half of A3G. By changing three
adjacent amino acids in A3A, to the sequence found in the N-terminal half of A3G, we were able to confer on
A3A the ability to be efﬁciently incorporated into HIV-1 virions and to bind HIV-1 Gag. Nevertheless, this A3A
mutant remained a weak inhibitor of HIV-1 infectivity, suggesting that segregation of the Gag-binding/virion
incorporation and cytidine deaminase/virus-inhibition activities of APOBEC3 proteins into two tandem CDA
regions promotes the efﬁcient inhibition of retrovirus infectivity by APOBEC3 proteins.
© 2008 Elsevier Inc. All rights reserved.Introduction
Members of the APOBEC3 family of cytidine deaminases have been
shown to function as innate inhibitors of retrovirus replication and
retrotransposon mobility (reviewed by Cullen, 2006). Seven APOBEC3
family members have been identiﬁed in humans, designated
APOBEC3A (A3A) through APOBEC3H (A3H). These proteins can be
further subdivided into ∼20 kDa proteins containing a single
consensus cytidine deaminase domain (CDA), i.e., A3A, APOBEC3C
(A3C) and A3H, and ∼40 kDa proteins containing two tandem CDAs,
i.e., APOBEC3B (A3B), APOBEC3F (A3F), APOBEC3G (A3G) and
APOBEC3D/E. How the duplication of the CDA facilitates the inhibitory
activity of these latter four proteins has remained largely unclear.
The antiretroviral potential of APOBEC3 proteins was ﬁrst
recognized in the case of A3G, which is a potent inhibitor of the
activity of HIV-1 mutants lacking a functional Vif gene product (HIV-
1ΔVif) (Sheehy et al., 2002). Infection of A3G-expressing cells by HIV-
1ΔVif mutant viruses results in the speciﬁc incorporation of A3G into
progeny virions. Upon subsequent infection, A3G interferes with the
HIV-1 reverse transcription process, at least in part by extensively
editing dC to dU on the nascent proviral DNA minus strand (Harris
et al., 2003; Mangeat et al., 2003; Yu et al., 2004; Zhang et al., 2003).
The overall effect of this is to severely inhibit the production of
functional, integrated HIV-1 proviruses. However, wild-type HIV-1
encodes the Vif protein, which binds A3G directly and induces its), bryan.cullen@duke.edu
l rights reserved.degradation by targeting A3G to the proteosome, thus protecting
HIV-1 from A3G-mediated inhibition (Conticello et al., 2003; Kao
et al., 2003; Marin et al., 2003; Mehle et al., 2004; Sheehy et al.,
2003; Yu et al., 2003).
While the basis for selective A3G packaging into HIV-1 virions
remains incompletely understood, it is known to be mediated by the
nucleocapsid domain of the HIV-1 Gag protein (Alce and Popik, 2004;
Cen et al., 2004; Luo et al., 2004; Schäfer et al., 2004; Zennou et al.,
2004). Within A3G itself, it has been reported that inactivating
mutations of the amino-terminal CDA, which extends from approxi-
mately residue 65 to 104 in A3G, reduce A3G virion incorporation,
while mutation of the carboxy-terminal CDA has little effect (Bogerd
et al., 2007; Navarro et al., 2005; Newman et al., 2005). Others have
reported that residues 107 to 162, or residues 105 to 156, both lying
outside the core CDA, are critical for HIV-1 virion incorporation of A3G
(Cen et al., 2004; Luo et al., 2004), and Huthoff and Malim (2007)
recently reported that A3G residues 124 to 127, a highly aromatic
amino acid stretch consisting of Tyr-Tyr-Phe-Trp (YYFW), play a
particularly important role in A3G virion incorporation.
Analysis of the residues in A3G required for Vif binding has
indicated that these also lie in the amino-terminal half of the
protein. Speciﬁcally, Zhang et al. (2008) have reported that A3G
residues 105 to 156 are essential for HIV-1 Vif binding but that A3G
degradation, surprisingly, also requires residues 157 to 245. Others
have demonstrated that the individual mutation of A3G residues
128–130 can totally block HIV-1 Vif binding (Bogerd et al., 2004;
Huthoff and Malim, 2007; Schrofelbauer et al., 2004). While the
amino-terminal half of A3G therefore contains all the sequences
required for HIV-1 virion incorporation and Vif binding, inhibition of
HIV-1 infectivity also requires the carboxy-terminal half of A3G. At
Fig. 1. Binding of APOBEC3 proteins to HIV-1 Gag correlates with virion packaging.
(A) The ability of wild-type and mutant forms of A3G and A3A to bind HIV-1 Gag was
determined by co-expressing in 293T cells the viral polyprotein with the indicated HA-
tagged APOBEC3 proteins, followed by co-immunoprecipitationwith a rabbit polyclonal
HIV-1 p24 antiserum. Proteins present in the lysate and co-immunoprecipitate (Co-IP)
were resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and analyzed by
Western blotting with amouse monoclonal antibody against HA (APOBEC) or HIV-1 p24
(Gag). (B) Full-length wild-type A3G and the A3G(DY) mutant, as well as the indicated
single-domain APOBEC3 proteins, were expressed in the context of HIV-1ΔVifΔEnv and
virion packaging evaluated. Proteins from cell lysates and puriﬁed virions were
analyzed by Western blotting as described above. (C) Amino acid alignment of selected
regions in the APOBEC3 proteins. The highlighted segments show the presence or
absence of the four-amino acid YYFW motif previously implicated in the HIV-1 virion
encapsidation of A3G (Huthoff and Malim, 2007).
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terminal CDA is, in fact, enzymatically active as a cytidine deaminase
(Hache, Liddament, and Harris, 2005; Iwatani et al., 2006; Miyagi
et al., 2007; Navarro et al., 2005; Newman et al., 2005; Schumacher
et al., 2008).
While A3G, as well as A3B and A3F, can all block HIV-1 infectivity
efﬁciently, other human APOBEC3 proteins have relatively weak
inhibitory activity (Doehle et al., 2005; Wiegand et al., 2004; Zheng
et al., 2004). In the case of A3A, recent data demonstrate that
inhibitory activity can be induced by fusion of A3A to the amino-
terminal half of A3G or to the HIV-1 Vpr protein, both of which induce
the recruitment of A3A into HIV-1 virion cores (Aguiar et al., 2008;
Goila-Gaur et al., 2007). These observations suggest that A3A, which
has a highly enzymatically active CDA (Bogerd et al., 2007), is unable to
restrict HIV-1 infectivity only because it is not selectively incorporated
into HIV-1 virion particles.
In this manuscript, we conﬁrm and extend these data by analyzing
the virion incorporation, HIV-1 Gag binding capacity and virusinhibitory activities of A3G and A3A mutants. In the case of A3G, we
show that the amino-terminal half (residues 1–196) of the 384 aa A3G
protein is sufﬁcient for HIV-1 virion incorporation and HIV-1 Gag
binding, while the carboxy terminal half (residues 197–384) neither
binds HIV-1 Gag nor is taken up into virion particles. Neither the A3G
(1–196) nor the A3G(197–384) protein was able to inhibit HIV-1ΔVif
infectivity when expressed in virus producing cells. The A3G(1–196)
protein, but not A3G(199–384), also binds HIV-1 Vif avidly. However,
A3G(1–196) is resistant to degradation and is therefore capable of
titrating out the Vif protein and thereby facilitating the inhibition of
wild-type HIV-1 infectivity induced by full-length A3G. Like A3G(197–
384), the wild-type A3A protein is not packaged into HIV-1 virion
particles. However, mutation of the analogous residues in A3A to the
critical 124-YYFW-127 packaging motif present in A3G resulted in
efﬁcient incorporation of A3A into HIV-1 virion particles. Surprisingly,
however, this was not reﬂected in an increased inhibition of virus
infectivity.
Results
Sequence requirements for virion incorporation and Gag binding by
APOBEC3 proteins
To more fully deﬁne the contributions of the amino-terminal and
carboxy-terminal halves of the A3G protein, each of which contains a
complete CDA, to the inhibition of HIV-1 infectivity, we expressed A3G
residues 1–196 and 197–384 as HA-tagged proteins and compared
their ability to bind HIV-1 Gag and to package into HIV-1 virions. For
this purpose, vectors expressing wild-type A3G, A3G(1–196), or A3G
(197–384) were co-transfected into 293T cells with an HIV-1 Gag
expression plasmid or a ΔVifΔEnv provirus vector. Virion incorpora-
tion was assessed by Western analyses of ΔVifΔEnv HIV-1 virus-like
particles collected from the supernatant media. In parallel, HIV-1 Gag
binding was assessed by immunoprecipitation of HIV-1 Gag using a
polyclonal rabbit p24 capsid antiserum followed by Western analysis
of the immunoprecipitate. In both cases, mouse monoclonals speciﬁc
for HIV-1 Gag or the HA epitope tag were used.
As shown in Fig. 1A, both wild-type A3G and A3G(1–196) bound to
HIV-1 Gag efﬁciently while A3G(197–384) failed to interact. As
expected, Gag binding fully predicted the ability to incorporate into
the HIV-1 virion particles that were released by the transfected cells
(Fig. 1B).
As noted above, A3A is a single CDA domain human APOBEC3
protein that does not effectively inhibit HIV-1 infectivity, even though
it is a highly active cytidine deaminase and a potent inhibitor of
retrotransposon mobility (Bogerd et al., 2006a, 2006b; Chen et al.,
2006; Muckenfuss et al., 2006). As shown in Fig. 1A, A3A is not able to
bind HIV-1 Gag effectively and this correlates with undetectable
incorporation into HIV-1 virion particles (Fig. 1B). A comparison of the
sequences of A3G and A3A showed that the 124-YYFW-127 sequence
motif found in the amino terminal region of A3G, which has been
reported to be critical for A3G incorporation into HIV-1 virions
(Huthoff andMalim, 2007), is lacking in not only the C-terminal region
of A3G but also in A3A (Fig. 1C). We therefore asked if mutagenesis of
A3A, to substitute the YDY sequence normally present in A3Awith this
YYFW motif (Fig. 1C), would enhance HIV-1 Gag binding and virion
incorporation. As shown in Fig. 1, the resultant A3A(YFW)mutant now
bound HIV-1 Gag effectively and was incorporated into HIV-1 virions.
Similarly, substitution of the wild-type YYFW motif present in A3G
with the YDY sequence found in A3A, in mutant A3G(DY) (Fig 1C),
blocked the incorporation of full-length A3G into HIV-1 virions (Fig.
1B) and also prevented binding to HIV-1 Gag (Fig. 1A). These data
conﬁrm the importance of the 124-YYFW-127 motif in A3G for HIV-1
Gag binding and virion incorporation and argue that its absence in
wild-type human A3A largely explains the poor incorporation of this
protein into HIV-1 virion particles.
Fig. 2. Packaging-competent single-domain APOBEC3 proteins do not inhibit HIV-1 infectivity. (A) The inhibitory activity of wild-type A3G, the A3G(DY) mutant, and each single-
domain APOBEC3 protein against HIV-1was quantiﬁed using the proviral reporter plasmid pNL-Luc-HXBΔVif. 50 ng of thewild-type or full-length A3G expression plasmid, or 200 ng
of each single-domain APOBEC3 vector, or of the A3G(DY) mutant expression plasmid, were co-transfected with the proviral construct. Virus-containing media were collected and
used to infect 293T cells. The infected cells were lysed and the level of luciferase activity measured. Results were normalized to a transfection lacking an APOBEC3 vector (control).
(B) The ability of wild-type A3A and the A3A(YFW) mutant to inhibit the mobility of the IAP LTR retrotransposon was assayed as previously described (Bogerd et al., 2006a). In this
assay system, IAP retrotransposition results in resistance to the antibiotic G418 and can be quantitated by counting the number of resistant colonies after co-transfectionwith an IAP-
based indicator construct and drug selection. Data are presented as a fraction of the number of retrotransposition events seen in the absence of any APOBEC3 protein. Average of three
experiments with standard deviation indicated. (C) Full-length A3G and the single-domain APOBEC3 proteins were co-expressed in the context of HIV-1ΔVifΔEnv-expressing cells
and the amount of A3G encapsidation evaluated. 293T cells were co-transfected with 50 ng phA3G-HA and 200 ng of a single-domain APOBEC3 vector. Proteins from cell lysates and
isolated virions were resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and analyzed byWestern blotting with a mouse monoclonal antibody against HA (APOBEC) or
HIV-1 p24 (Gag). (D) The inhibitory activity of A3G, co-expressedwith each single-domain APOBEC3 protein, was examined. In this case, 50 ng of phA3G-HAwere co-transfected with
200 ng of each single-domain APOBEC3, along with a reporter provirus. Infection of 293T cells and quantiﬁcation was carried out as described in A. The results were normalized to a
transfection lacking any APOBEC3 vector (control).
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Given recent data showing that A3A can inhibit HIV-1 infectivity
when recruited into HIV-1 virion particles by fusion to the amino-
terminal half of A3G or to the HIV-1 Vpr protein (Aguiar et al., 2008;
Goila-Gaur et al., 2007), we were curious whether the A3A(YFW)
mutant would have acquired antiviral activity against HIV-1 due to its
enhanced virion incorporation (Fig. 1B). However, we did not see
signiﬁcant antiviral activity from any of the single CDA domain
APOBEC3 proteins, including A3A(YFW). Only the wild-type A3G
protein could inhibit HIV-1 infectivity effectively, and this inhibition
was blocked in the A3G(DY) mutant (Fig. 2A). It seemed possible that
the mutation introduced into A3A(YFW), while conferring the ability
to bind HIV-1 Gag and package into HIV-1 virion particles (Fig. 1)
might also have inhibited the biological activity of A3A. To address thisquestion, we asked if the A3A(YFW) mutant retained its ability to
inhibit the mobility of the murine LTR-retrotransposon IAP in co-
expressing cells (Bogerd et al., 2006a). As shown in Fig. 2B, both A3A
and the A3A(YFW) mutant in fact inhibited IAP retrotransposition by
the same ∼8 fold. Moreover, A3A and A3A(YFW) also inhibited the
mobility of the human non-LTR retrotransposon LINE1 to a similar
degree and A3A(YFW) also retained the ability to induce a hypermu-
tation phenotype when expressed in bacteria (data not shown), thus
indicating that the A3A(YFW) mutant retained cytidine deaminase
activity (Bogerd et al., 2006b). We therefore conclude that the inability
of the A3A(YFW) mutant to inhibit HIV-1 infectivity is not due to loss
of biological activity.
As the A3G(1–196) and the A3A(YFW) mutants are effectively
incorporated into HIV-1 virion particles, yet do not inhibit HIV-1
infectivity, we were curious to see if overexpression of A3G(1–196) or
Fig. 3. Binding of single-domain APOBEC3 proteins to HIV-1 Vif does not correlate with
Vif-sensitivity. (A) The ability of wild-type or mutant full-length A3G, and of various
single-domain APOBEC3 proteins, to bind HIV-1 Vif was determined by co-expressing
Vif with the indicated HA-tagged APOBEC3 proteins in 293T cells, followed by
immunoprecipitation with a mouse monoclonal anti-HA antibody. Proteins present in
the lysate and co-immunoprecipitate (Co-IP) were resolved by SDS-PAGE, transferred to
a nitrocellulose membrane, and analyzed by Western blotting with a rabbit polyclonal
antibody against HA (APOBEC) or rabbit polyclonal antisera speciﬁc for HIV-1 Vif (Vif).
(B) Each wild-type or mutant APOBEC3 protein's sensitivity to HIV-1 Vif was compared
to that of wild-type A3G by co-transfecting into 293T cells the respective APOBEC3
expression constructs together with empty pcDNA3 (−Vif) or pcDNA-HVif (+Vif) and
pNL4-3ΔVifΔEnv. Cell lysates were harvested and protein expression levels analyzed by
Western blotting with a rabbit polyclonal antisera speciﬁc for the HA epitope (APOBEC)
or HIV-1 p24 (Gag). The presence of HIV-1 Vif was probed with the rabbit polyclonal
antisera described in panel A.
Fig. 4. Vif-binding single-domain APOBEC3 proteins can rescue A3G from Vif-mediated
degradation. 293T cells were co-transfected with 50 ng phA3G-HA, 50 ng pcDNA-HVif,
and 200 ng (lanes 3, 5, 7, 9) or 500 ng (lanes 4, 6, 8, 10) of a vector encoding a single-
domain APOBEC3 protein. The proviral clone pNL4-3ΔVifΔEnv was also co-transfected.
Cell lysates were harvested and protein expression levels analyzed by Western blotting
with mouse monoclonal antibodies speciﬁc for the HA epitope (APOBEC) or HIV-1 p24
(Gag). The presence of HIV-1 Vif was probed with a rabbit polyclonal antisera.
Fig. 5. Rescue of wild-type A3G inhibition of HIV-1 by inhibition of Vif function.
(A) Expression plasmids were co-transfected into 293T cells as described in Fig. 4, with
two exceptions: the wild-type proviral reporter construct pNL-Luc-HXB was used in
place of pNL4-3ΔVifΔEnv and pcDNA-HVif was omitted. The experiment resulted in a
similar rescue of full-length A3G expression by A3G(1–196) in the presence of Vif and
thereby also enhanced A3G virion incorporation. (B) The effect of the enhanced A3G
expression induced by A3G(1–196) on wild-type HIV-1 virion infectivity is represented
by the white columns. These data show virus infectivity in the presence of only the
single-domain APOBEC3 proteins, i.e., in the absence of A3G (gray columns), or in
the presence of both full-length A3G and the truncated A3G protein (white columns).
The control samples display wild-type HIV-1 infectivity in the absence of any APOBEC
protein (gray column) or in the presence (white column) of full-length A3G only.
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inhibit HIV-1 infectivity by competing for packaging into virion
particles. As shown in Fig. 2C, while A3G(1–196) and A3A(YFW) were
indeed efﬁciently incorporated into HIV-1 virions produced in their
presence, this did not reduce the incorporation of a constant level of
wild-type A3G expressed in the same cells. Moreover, neither the A3G
(1–196) protein nor the A3A(YFW) protein, or indeed A3G(197–384)
or wild-type A3A, had any obvious effect on the level of inhibition of
HIV-1 infectivity induced by wild-type A3G (Fig. 2D). We therefore
conclude that the incorporation of A3G into HIV-1 virions is not
readily saturated, as also previously reported by Xu et al. (2007).
Vif binding by A3G and A3A mutants
As noted above, the domain in A3G required for Vif binding has
been previously mapped to the amino-terminal half of the protein,
closely proximal to, but distinct from, the sequences required for HIV-
1 Gag binding (Huthoff and Malim, 2007; Zhang et al., 2008). Analysis
of the two A3G “half-proteins” conﬁrmed these earlier reports, as both
A3G and A3G(1–196) were found to bind HIV-1 Vif effectively, while
the A3G(197–384) protein failed to interact (Fig. 3A). Surprisingly,
while wild-type A3A also failed to bind HIV-1 Vif, the A3A(YFW)
mutant had acquired the capacity to interact with Vif, thus suggesting
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overlap. However, while the A3G(DY) mutant had lost the ability to
interact with HIV-1 Gag (Fig. 1A), it retained a reduced but readily
detectable ability to interact with the HIV-1 Vif protein (Fig. 3A).
Analysis of the ability of HIV-1 Vif to induce degradation of these
APOBEC3 proteins revealed that wild-type A3G was effectively
degraded while both A3G(1–196) and A3A(YFW) were unaffected
(Fig. 3B). These data, while in some ways surprising, nevertheless
conﬁrm the previous observation (Zhang et al., 2008) that the Vif
binding site on A3G can be mutationally segregated from the
sequences required for A3G proteosomal degradation. Moreover, Vif
also failed to induce signiﬁcant degradation of the A3G(DY) mutant
(Fig. 3B), despite its ability to bind A3G(DY) in co-expressing cells
(Fig. 3A). This result is similar to data reported recently by Marin et al.
(2008), who reported that HIV-1 Vif can bind to two other members
of the APOBEC3 protein family, A3B and A3C, without inducing a
signiﬁcant level of degradation in vivo.
Inhibition of HIV-1 Vif function
If A3G(1–196) and A3A(YFW) can bind Vif while not being
degraded, then these proteins should have the potential to act as
competitive inhibitors of Vif function by sequestering Vif into an
inactive complex. Indeed, as shown in Fig. 4, expression in trans of
either A3G(1–196) or A3A(YFW) rescued the expression of wild-type
A3G in Vif-expressing cells. In contrast, neither A3G(197–384) nor
wild-type A3A, neither of which is able to bind to Vif (Fig. 3A), was
able to exert this protective effect (Fig. 4).
If A3G(1–196) can protect wild-type A3G from degradation in Vif-
expressing cells, then it should also rescue the incorporation of A3G
into HIV-1 virions and thereby indirectly reduce the infectivity of
those virions. To test this hypothesis, we co-transfected 293T cells
with a wild-type A3G expression vector, a truncated A3G mutant
expression vector and an expression plasmid encoding a Vif+ HIV-1
provirus bearing the luciferase indicator gene in place of Nef. As
shown in Fig. 5A, wild-type A3G expression was again enhanced by
overexpression of the A3G(1–196) but not the A3G(197–384) protein.
More importantly, A3G(1–196) signiﬁcantly enhanced the ability of
wild-type A3G to inhibit HIV-1 infectivity, while the A3G(197–384)
protein exerted no detectable effect (Fig. 5B). Therefore, A3G(1–196)
can indeed at least modestly boost wild-type A3G stability and
function when expressed in trans in HIV-1 Vif expressing cells.
Discussion
Although A3A is a highly active cytidine deaminase and a potent
inhibitor of several different retrotransposons (Bogerd et al., 2006a;
Bogerd et al., 2006b; Chen et al., 2006; Muckenfuss et al., 2006), it
nevertheless fails to appreciably inhibit HIV-1 infectivity (Fig. 2A). A3A
also fails to interact with HIV-1 Gag in co-expressing cells and is not
selectively packaged into HIV-1 virion particles (Fig. 1), although it
does package into virions non-selectively when overexpressed at
levels that also lead to the incorporation of irrelevant cytoplasmic
proteins, such as β-arrestin (data not shown). As fusion of A3A to the
amino-terminal half of A3G, or to the HIV-1 Vpr protein, induces both
the virion incorporation of A3A and inhibition of HIV-1 infectivity
(Aguiar et al., 2008; Goila-Gaur et al., 2007), it appeared that the
inactivity of wild-type A3A could be readily explained as being due
simply to its inability to be selectively packaged by HIV-1 virions.
In this report, we show that HIV-1 Gag binding by A3A, and HIV-1
virion incorporation, can be induced by mutation of A3A to induce a
“YYFW”motif that has been previously reported to be critical for HIV-
1 virion incorporation of A3G (Huthoff and Malim, 2007). These data
serve to conﬁrm the critical importance of this aromatic amino acid
sequence in HIV-1 virion packaging (Fig. 1B) and extend these earlier
data by demonstrating that the integrity of the “YYFW”motif in A3G isalso critical for HIV-1 Gag binding (Fig. 1A). These observations also
allowed us to test the hypothesis that non-fused A3A would be an
effective inhibitor of HIV-1 infectivity if it was taken up into HIV-1
virion particles. In fact, however, the A3A(YFW) mutant is not an
effective inhibitor of HIV-1 infectivity (Fig. 2A), even though it retains
full inhibitory activity against retrotransposons such as IAP (Fig. 2B).
The observation that the 124-YYFW-127 motif in A3G is critical for
binding to HIV-1 Gag implies either that this highly hydrophobic
sequence is located on the surface of the A3G protein or that mutation
of this sequence, by substitution of amino acids found at this same
location in A3A, results in themisfolding of the A3G protein. This latter
hypothesis seems unlikely, given that substitution of the YYFW motif
into A3A, to give the A3A(YFW) mutant, actually confers both HIV-1
Gag binding and virion packaging on the otherwise excluded A3A
protein (Fig. 1). Moreover, modelling of the structure of A3G, using the
reported APOBEC2 crystal structure as a starting point, as well as the
recently reported crystal structure of residues 198 to 384 of A3G, both
predict that these aromatic amino acid residues are expressed at the
surface of the A3G protein, where they can directly participate in
protein–protein interactions (Chen et al., 2008; Zhang et al., 2007).
The ﬁnding that A3A, a single CDA-domain APOBEC3 protein, is not
an effective inhibitor when packaged into HIV-1 virion particles
suggests that the duplication of the CDA domain seen in human A3G,
A3F and A3B, all of which are effective inhibitors of a range of
retroviruses (Cullen, 2006), may represent an important step in their
evolution. Speciﬁcally, the ﬁnding that A3A is not an effective inhibitor
of HIV-1 infectivity when engineered to enter HIV-1 virions by
binding to Gag (Figs. 1 and 2), yet is an effective inhibitor when
recruited into HIV-1 virions by fusion to either the amino-terminal
half of A3G (Goila-Gaur et al., 2007) or the viral Vpr protein (Aguiar et
al., 2008), suggests that a single CDA cannot effectively mediate both
retroviral packaging and inhibition of HIV-1 infectivity. In other
words, effective inhibition of retroviral infectivity requires segregation
of these two activities, i.e., Gag binding and virion packaging on the
one hand and inhibition of infectivity and cytidine deaminase function
on the other hand, into two tandem CDA domains present in a single
protein. According to this hypothesis, the single CDA domain A3A
protein can only function as an effective inhibitor of HIV-1 infectivity
when it is fused to a separate domain that confers packaging, i.e.,
either the amino-terminal half of A3G or HIV-1 Vpr (Aguiar et al.,
2008; Goila-Gaur et al., 2007).
The data presented in this manuscript conﬁrm and extend
previous work suggesting that the amino-terminal half of A3G, i.e.,
residues 1–196, indeed contains all the sequences required for HIV-1
Gag binding and HIV-1 virion incorporation (Cen et al., 2004; Luo
et al., 2004; Miyagi et al., 2007; Navarro et al., 2005; Schumacher et al.,
2008) (Fig. 1) yet is not capable of inhibiting HIV-1 infectivity (Fig. 2A).
Interestingly, overexpression of A3G(1–196) or A3A(YFW), both of
which package effectively, failed to reduce the packaging of wild-type
A3G expressed in the same cell (Fig. 2C) or inhibition of HIV-1
infectivity by wild-type A3G (Fig. 2D), thus conﬁrming a previous
report suggesting that A3G incorporation into HIV-1 virions is not
readily saturated (Xu et al., 2007).
In addition to binding Gag, the A3G(1–196) and A3A(YFW)
mutants also bound HIV-1 Vif effectively, although neither protein–
unlike wild-type A3G–was found to be destabilized by Vif (Fig. 3).
These results suggest that the sequences in A3G that mediate binding
to HIV-1 Gag and HIV-1 Vif likely overlap extensively, as insertion of
the YFW motif previously deﬁned by Huthoff and Malim (2007) as
critical for A3G packaging into HIV-1 virions conferred the ability to
bind both HIV-1 Gag and HIV-1 Vif (Figs. 1 and 3). Of interest, it has
previously been argued that HIV-1 Vif can block A3G virion
incorporation without inducing its degradation, a result that would
be consistent with the idea that HIV-1 Gag and HIV-1 Vif compete for
binding to overlapping sites on the A3G protein (Opi et al., 2007). On
the other hand, the A3G(DY) mutant, which had entirely lost the
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bind the HIV-1 Vif protein (Fig. 3A), thus demonstrating that the HIV-1
Gag and HIV-1 Vif binding motifs in A3G must be at least partly
distinct.
Because A3G(1–196) binds Vif yet is not degraded (Fig. 3), we asked
if A3G (1–196) would be able to facilitate the inhibition of wild-type
HIV-1 by wild-type A3G by sequestering Vif into an inactive complex.
In fact, both A3G(1–196) and A3A(YFW) proved able to inhibit the
degradation of wild-type A3G by Vif in co-expressing cells (Figs. 4 and
5A), and A3G (1–196) also reduced the infectivity of wild-type HIV-1
virions produced in the presence, but not the absence, of full-length
A3G (Fig. 5B). In contrast, A3G(197–384) had no effect in this assay.
These data contrast with a recent report (Zhang et al., 2008) which
argued that either residues 1–156 or residues 157–384 of A3G, when
expressed in cells, can dominantly inhibit the Vif-mediated degrada-
tion of wild-type A3G. The reasons for the difference between our data
and this earlier report are not clear, but could reﬂect the expression of
different segments of A3G.
In conclusion, our data further conﬁrm the proposal (Navarro et al.,
2005) that the amino-terminal and carboxy-terminal CDAs of A3G
fulﬁl distinct roles during inhibition of retroviral infectivity and
suggest that the functional separation of the virion packaging and
enzymatic activities of A3G into two tandem CDA domains facilitates
the efﬁcient inhibition of retroviral infectivity.
Materials and methods
Cell culture and reagents
293T cells were cultured in DMEM containing 10% FBS. All
transfections were performed using the calcium phosphate method
in six-well plates. Protein A and rProtein G agarose were purchased
from Invitrogen. Puriﬁed mouse monoclonal and rabbit polyclonal
antibodies against hemaglutinin (HA) were purchased from Covance.
The mouse monoclonal antibody (Cat.# 3537) (Chesebro et al., 1992)
and rabbit polyclonal antisera (Cat.# 4250) speciﬁc for capsid (p24) of
the HIV-1 Gag polyprotein, as well as the rabbit polyclonal antisera
against HIV-1 Vif (Cat.#2221) (Goncalves et al., 2002), were obtained
through the AIDS Research and Reference Reagent Program. Reporter
virus luciferase activity was quantiﬁed using the Luciferase Assay
System from Promega and light emissionmeasured using a Turner TD-
20/20 luminometer.
Molecular clones
The HIV-1 proviral expression plasmids pNL-Luc-HXB, pNL-Luc-
HXBΔVif and pNL4-3ΔVifΔEnv have been previously described
(Bogerd et al., 2004), as have the pcDNA3-based expression plasmids
phA3A-HA and phA3G-HA (Wiegand et al., 2004). The plasmid
psynGag, encoding a codon optimized HIV-1 Gag protein, has also
been described (Doehle, Schafer, and Cullen, 2005). HIV-1 Vif was
expressed from the partially codon-optimized vector pcDNA-HVif,
which was obtained through the AIDS Research and Reference
Reagent Program (Cat. # 10077) (Nguyen et al., 2004). pHIT/G was
used to pseudotype HIV-1 infection. Vectors expressing either amino
acids 1–196 (phA3G 1–196) or 197–384 (phA3G 197–384) of A3G,
each containing a C-terminal triple HA epitope tag, were generated
from phA3G-HA. Brieﬂy, the desired coding regions were ampliﬁed by
PCR and subcloned into phA3G-HA, which had been digested with
Asp718/EcoRI to remove the A3G coding region, leaving the HA tag
intact. The vector expressing the A3A(YFW) mutant, where amino
acids D131 and Y132 are replaced with the amino acid sequence YFW,
was constructed from phA3A-HA by recombinant PCR. The A3G(DY)
mutant, which contains the opposite mutation, was also generated by
recombinant PCR. The integrity of all the expression vectors used in
this analysis was conﬁrmed by DNA sequencing.Co-immunoprecipitations
For co-immunoprecipitation of HIV-1 Gag and APOBEC3 proteins,
293T cells were co-transfected with 500 ng of a plasmid expressing a
wild-type or mutant APOBEC3 protein and 100 ng of the psynGag
vector. At 40 h post-transfection, the cells were lysed with 50 mM
Tris, pH 7.4/150 mM NaCl/0.5% NP-40 and the lysate clariﬁed by brief
centrifugation. A portion of the clariﬁed lysate was removed for
subsequent analysis while the remainder was added to 30 μl of
equilibrated Protein A agarose. Two μl of HIV-1 p24 rabbit polyclonal
antisera were added to the matrix and the suspension mixed for 3 h
at 4 °C. The matrix was washed extensively then suspended in
loading buffer. Equal aliquots of the total and bound fractions were
subjected to denaturing gel electrophoresis and transferred to a
nitrocellulose membrane. The membrane was probed with mouse
mAb speciﬁc for either the HA epitope or HIV-1 p24 of the Gag
polyprotein.
The procedure outlined above was also used for co-immunopre-
cipitation of APOBEC3 proteins and HIV-1 Vif, with the following
exceptions: Expression plasmids for the APOBEC3 proteins and
pcDNA-HVif were co-transfected in equal 500 ng amounts. Clariﬁed
lysate was added to rProtein G agarose, and the APOBEC3 and Gag
proteins were co-immunoprecipitated with a mouse mAb speciﬁc for
the HA epitope. Following electrophoresis and transfer, the nitrocel-
lulose membrane was probed with rabbit antisera speciﬁc for the HA
epitope or for the HIV-1 Vif protein.
Viral packaging of APOBEC3 proteins
To examine expression and virion packaging of the APOBEC3
proteins in the context of virus production, 293T cells were co-
transfected with 1500 ng pNL4-3ΔVifΔEnv, 100 ng of an APOBEC3
vector, and 500 ng of pcDNA3 ﬁller. In the case of more complex
experiments where A3G is expressed concomitantly with one of the
single-domain APOBEC3 proteins, cells were co-transfected with
1500 ng of the indicated proviral vector, 50 ng phA3G-HA, and 200
or 500 ng of a single-domain APOBEC3 plasmid. The total amount of
DNA transfectedwas kept constant using the parental pcDNA3 as ﬁller.
Approximately 40 h post-transfection, 1.2 ml of virus containing
media were collected and passed through a 0.45 μm ﬁlter onto 300 μl
of a 20% (wt/vol) sucrose cushion in a microcentrifuge tube. Virus was
pelleted by centrifugation at 21,000 rcm for 2 h at 4 °C. The media
were decanted and the pelleted virus was resuspended in loading
buffer. Relative amounts of lysate and virion incorporated APOBEC3
and Gag proteins were analyzed by Western blotting with a mouse
mAb for HA or HIV-1 Gag polyprotein.
Virus infection and luciferase assay
293T cells were co-transfected with 1500 ng pNL-Luc-HXB or pNL-
Luc-HXBΔVif, indicated amounts of phA3G-HA, 50 ng pHIT/G, and 200
or 500 ng of a single-domain APOBEC3 plasmid. The total amount of
DNA transfectedwas kept constant using the parental pcDNA3 as ﬁller.
Approximately 40 h post-transfection, the supernatant media were
collected and ﬁltered as described above, and used to infect 293T cells.
The virus-producing cells were lysed and probed for expression of the
relevant proteins. Infected cells were assayed 24 h later for luciferase
activity.
Vif-sensitivity of APOBEC3 proteins
293T cells were co-transfected with 1500 ng pNL4-3ΔVifΔEnv,
200 ng of an APOBEC3 vector, and 500 ng pcDNA-HVif or pcDNA3
parental vector. Cells were harvested 40 h post-transfection and
relative protein levels were assayed by Western blot, as described
above.
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